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INTRODUCTION
Bronchial hyperresponsiveness (BHR) is a 
condition of excessive airway irritability and 
the factor in predicting bronchial asthma inde-
pendently of inflammation markers. BHR in 
asthmatic children is a consequence of chronic 
immunologic inflammation with stimulative 
tendency of developing bronchial obstruc-
tion during a response to different stimuli. 
An appropriate procedure to verify bronchial 
hyperresponsiveness in children is a broncho-
provocation test with methacholine. There is a 
huge causality between the clinical difficulty of 
bronchial asthma with applied medications on 
one side and BHR on the other.
The treatment of bronchial asthma aims at 
enabling the child to engage in normal every-
day activities, more exactly to be involved in 
physical activities and sport without restric-
tions. The therapy of bronchial asthma should 
relieve the child of respiratory discomforts 
during the day and night, enabling attendance 
of nursery or school. Moreover, its purpose is 
to establish a normal lung function with low 
daily variations of peak expiratory flow (PEF), 
as well as adequate bronchial responsiveness. 
The most effective medications for treatment of 
childhood asthma are inhaled corticosteroids, 
which are the first line of therapy in children 
who suffer from severe persistent and moder-
ately persistent asthma. The recommended 
therapy by the British Guidelines [1] and a 
number of authors such as Nielsen and Bisgaard 
[2] recommend for children who suffer from 
severe persistent asthma high doses of inhaled 
corticosteroids (800-2000 μg of beclometha-
sone dipropionate per day), long-acting bron-
chodilatators, sustained-release theophylline, 
long-term use of oral corticosteroids, urgent 
application of quick-relief medications, such 
as inhaled short-acting β2-agonist and appli-
cation of immunomodulators.
Children who suffer from severe refractory 
steroid depended asthma and steroid inde-
pended asthma have poor response to usual 
conventional therapy and demand a long-last-
ing use of medications with anti-inflammatory 
and immunomodulatory effects, and accord-
ing to Rabinovitch et al. [3] intake of immu-
noglobulin G.
OBJECTIVE
The aims of our study were to determine the 
frequency and important predictive facts on 
BHR and the effect of prophylaxis by GINA 
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(Global Initiative for Asthma) [4] and NAEPP (National 
Asthma Education and Prevention Program) [5] on BHR 
in children who suffer from asthma.
METHODS
In our study BHR was evaluated by a bronchoprovocation 
test with methacholine and a modified Cockcroft proto-
col [6]. We used methacholine chloride powder for inhala-
tion (Methapharm®, Canada), a spirometer (Jaeger Master 
Scope®) and a compressed nebuliser with corresponding 
aerosol flow and the size of particles. A bronchoprovo-
cation test with methacholine was done in 2006 and was 
repeated two years later, in 2008. In the study 106 children 
aged 10 years were randomly selected from general paedi-
atric population. Based on exclusion criteria ten children 
were eliminated, and the final studied group involved 96 
children. Including criterions for asthmatic children were 
determined based on the GINA guidelines and accord-
ingly the excluding criterions.
A statistical analysis was carried out by ANOVA one-
factor and two-factor analysis of results, using the program 
SPSS. Data were obtained at the 5% significance level with 
90% certainty, assuming on 2 SD. Time was included as a 
descriptive parameter and the analysis of covariance was 
used. The estimate of the significance of difference was 
performed by Pearson test, Fisher test, Kruskal–Wallis 
test, Student t-test, Mann–Whitney U-test, Wilcoxon Rank 
Sum W-test and Spearman’s coefficient of correlation with 
regression analysis.
RESULTS
Of 96 studied children, BHR was revealed in 21 (22%) of 
whom 17 children (18%) had bronchial asthma. In the asth-
matic children, atopic and non-atopic, we repeated bron-
choprovocation test with methacholine after administering 
prophylaxis. The results are shown in Graphs 1, 2, 3 and 4.
In the 17 asthmatic children who underwent the bron-
choprovocation test with methacholine in 2006 we found 
that the average value of provocation dose of methacholine 
that caused a 20% fall in the FEV1 with initial value (PD20) 
which was 1.51±1.23 μmol of methacholine; the average 
value of provocation concentration of methacholine (PC20) 
was 1.66±1.52 mg/ml, and the average value of provocation 
concentration of methacholine causing wheezing (PCw) 
was 1.66±1.52 mg/ml methacholine, which corresponded 
to the fall of FEV1 for 35±14% on average, with an aver-
age slope of dose response curve for 83±139, and to a loga-
rithmic value of slope of dose response curve of 1.46±0.61.
In June, 2008, we repeated a bronchoprovocation test 
with methacholine in the same group of children, and we 
found average PD20 of 1.94±1.24 μmol methacholine, aver-
age PC20 of 2.18±1.37 mg/ml methacholine and average 
PCw of 0.60±0.61 mg/ml methacholine, which corre-
sponded to a fall in the FEV1 on average for 26±6%, to 
average slope dose response curve for 165±593 and to loga-
rithmic value of slope dose response curve for 1.31±0.64.
Bronchial sensitivity in asthmatic children, in other 
words, the provocation dose of methacholine (PD20) that 
causes a 20 per cent fall in the FEV1 as the provocation 
concentration of methacholine (PC20) that caused a 20 
per cent and more fall in the FEV1 was approximately the 
same regardless of the year when the bronchoprovoca-
tion test was performed (Pearsons’ coefficient of correla-
tion r=0.7920, p=0.000; Pearsons’ coefficient of correlation 
r=0.8794, p=0.000). Bronchial reactivity in asthmatic chil-
dren, in other words the logarithmic value of slope dose 
response curve (logSDR=%dFEV1/μmol) was on aver-
age significantly lower in 2008 (1.31±0.64) than in 2006 
(1.46±0.61) for a given threshold of bronchial response 
(Pearsons’ coefficient correlation r=0.4625, p=0.062). In 
Graph 1. Bronchial sensitivity (BS) and bronchial reactivity (BR) in regard to the degree of bronchial hyperresposiveness (BH) in asthmatic children in 2006
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2006, bronchial reactivity was low (logSDR<1.1) in six chil-
dren (6%), whereas in 2008 it was low in 10 children (10%) 
(logSDR<1.3). The change of FEV1 rate (%dFEV1) was 
significantly lower in asthmatic children in 2008, mean-
ing that the correlation between the values of %dFEV1 in 
2006 and 2008 were relatively low (Pearsons’ coefficient 
of correlation r=0.2944, p=0.251). The results are shown 
in Graphs 1, 2 and 3.
The velocity of change of slope dose response curve 
(σlogSDR) in the asthmatic children was obtained by a 
mathematic extrapolation of the results, as shown in graph 
3. In the asthmatic children the velocity of change of slope 
dose response curve was faster in 2008 than in 2006. The 
velocity of logarithm of slope of dose response curve for 
every PC20 in 1996 was calculated using the formula: 
σlogSDR = 0.2472 × PC203 - 1.6617 × PC202 + 3.4275 
Graph 3. The velocity of change of slope dose response curve in asth-
matic children in 2006 and 2008
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Graph 2. Bronchial sensitivity (BS) and bronchial reactivity (BR) in regard to the degree of bronchial hyperresponsiveness (BH) in asthmatic children in 2008
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Graph 4. Relation between PCw and degree of bronchial hyperresponsiveness (BH) in asthmatic children in 2006 and 2008
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× PC20 - 2.4216, and in 2008 it was calculated by using the 
formula: σlogSDR = 0.4756 × PC203 - 3.2711 × PC202 
+ 6.9145 × PC20 - 4.6516.
The appropriate slopes of dose response curve (83±139; 
165±593) and the appropriate values of PD20 (1.51±1.23 
μmol; 1.94±1.24 μmol, respectively) in relation to the 
crucial point of PD20≤3.99 μmol methacholine showed 
moderate bronchial hyperresponsiveness in the major-
ity of the asthmatic children, regardless of the year when 
the study was conducted. In children that showed moder-
ate and severe bronchial hyperresponsiveness, elevated 
bronchial sensitivity to methacholine (PD20≤1.7 μmol; 
PD20≤1.5 μmol) was promptly followed by elevated bron-
chial reactivity to methacholine (logSDR≥1.1; logSDR≥1.3), 
regardless of the year when bronchial responsiveness was 
measured. The bronchial reactivity measured in 2008 was 
significantly fast in six asthmatic children (6%).
The provocative concentration of methacholine that 
caused wheezing (PCw) in the asthmatic children was 2 to 
3 times more favourable in 2008 (1.66±1.51 mg/ml) than 
in 2006 (0.60±0.61 mg/ml), and there was a slight corre-
lation between the mentioned values of PCw (Pearsons’ 
coefficient correlation r=0.3731, p=0.140). The results are 
shown in Graph 4.
The bronchoprovocation test with methacholine in the 
asthmatic children was concluded by the use of broncho-
dilatator (salbutamol). During 2006 study period, in asth-
matic children the bronchodilatator response (+20%FEV1) 
lasted 19±8 minutes, whereas in 2008 the bronchodilata-
tor response was slightly faster (13±5 minutes) and with 
a significant correlation (Pears’ coefficient correlation 
r=0.6883, p=0.002).
Thanks to our colleagues from the Public Health Insti-
tute in Kragujevac, during 2006 and 2008 we received data 
on the average quantity of the total disposed waste, pollut-
ans, sulfur dioxide (SO2) and soot. We did not have any 
data on the concentration of nitric dioxide due to the fact 
that there were no measurements taken in our area. We 
obtained data by the beginning of 2001 and by the end 
of 2008 after having completed our research and we can 
accept them only as a supplement to the discussion of our 
results.
Air-pollutants from the deposited waste (859 mg/m2 
per day) exceeded the allowed upper limit mostly in the 
centre of the city, i.e. the location of the school where we 
carried out our first study in the period of June, 2006. In 
the second study period of June 2008, the quantity of total 
deposited waste was 2.5 times lower (339 mg/m2 per day) 
than in the same month two years earlier.
The upper limit of SO2 concentration was 150 μg/m3 
per day. In June 2006, the average monthly value (amv 
or av/m.) of SO2 was 32 μg/m3 per day exceeding the 
upper limit of SO2 during one day (195 μg/m3 per day). 
Two years later, we repeated the bronchoprovocation test 
and measured aero-pollution in the centre of the city. In 
June 2008, the average monthly value of SO2 was 3.4 times 
higher than in June 2006, reaching 108 μg/m3 per day. The 
upper limit of SO2 was exceeded during four days, with a 
maximum value of 165 μg/m3 per day. It is interesting to 
mention that the upper limits of SO2 were exceeded at the 
beginning of June 2006 and June 2008.
In May 2006 the concentration of SO2 was within the 
limited range (29 μg/m3 per day) as in May 2008 (70 μg/m3 
per day). The upper limit of SO2 was exceeded during one 
day in May 2008. The upper limit concentration of soot 
concentration was 50 μg/m3 per day. The concentration 
of soot in June 2006 and in June 2008 varied within the 
limited range, and the upper limit was not exceeded.
DISCUSSION
The prevalence rate of symptomatic bronchial hyperre-
sponsiveness in a random sample of 106 children in our 
region is 18% for crucial point of PC20=4.1±3.03 mg/ml 
and PD20=3.22±2.59 μmol methacholine. Chinn et al. [7] 
concluded that respiratory symptoms more frequently pres-
ent in children from Australia, New Zealand, West Coast 
of America and England than in children from continen-
tal Europe. Peat et al. [8] from Australia found in his study 
that symptomatic bronchial hyperresponsiveness ranged 
from 19% in children that previously exhibited wheezing 
to 48% in children that exhibited wheezing during the last 
12 months. Symptomatic bronchial hyperresponsiveness 
was reported by Ulrik [9] to be present in 15% of children 
from Denmark aged 7-17 years, by Siersted [10] in 75% 
of children aged 12-15 years, by Backer [11] in 35% and 
by Hansen et al. [12] in 82%. In Omaha, according to the 
results obtained by Hopp et al. [13], 98% of children express 
symptomatic bronchial hyperresponsiveness, whereas Popp 
et al. [14] reports 65% children who express symptomatic 
bronchial hyperresponsiveness in Austria. The prevalence 
rate of symptomatic bronchial hyperresponsiveness in our 
region is on average in relation to the prevalence rate in 
other countries worldwide.
During our research, we detected that asthmatic chil-
dren expressed on average a moderate bronchial hyperre-
sponsiveness which continued two years after prophylaxis 
by GINA and NAEPP.
Bronchial sensitivity in asthmatic children is approxi-
mately the same before and two years after administering 
the prophylaxis. However, bronchial reactivity is signif-
icantly lower two years after prophylaxis. In asthmatic 
children the change of FEV1 is significantly smaller, the 
velocity of change of slope dose response curve is faster, 
PCw is 2-3 times lower and bronchodilatation response 
(+20%FEV1) is slightly faster after two years of prophy-
laxis by GINA and NAEPP.
Children who exhibit moderate and severe bronchial 
hyperresponsiveness, low bronchial sensitivity to metha-
choline is followed by a prompt and elevated bronchial 
reactivity to methacholine, bearing in mind that after two 
years of conventional prophylaxis by GINA and NAEPP, the 
slope of dose response curve in the middle part has been 
milder. The smaller steep slope of the dose response curve 
shows that bronchoconstriction is milder after two years 
of prophylaxis. The airways of the treated and controlled 
asthmatic patient are less constricted; the growth of inflam-320
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mation cells is slower and they release constrictor media-
tors in small quantities, so that the child does not exhibit 
symptoms, or exhibits only mild symptoms of asthma after 
two years of conventional therapy [4, 5].
The children from our study had asthma exacerbations 
despite the fact that they needed prolonged treatment with 
the aim to reach minimal bronchial reactivity and high 
bronchial sensitivity.
After two years of conventional prophylaxis the children 
were free of symptoms and exhibited a moderate bronchial 
responsiveness. Devereux et al. [15], Avital et al. [16], Barr 
et al. [17] and Szefler et al. [18] explained that the reason 
for absent coordination between the patient’s history and 
bronchoconstriction to methacholine is not due to poor 
perception, but to poor subjective description of the feel-
ing of bronchoobstruction. Sunyer et al. [19] considered 
wheezing highly sensitive for bronchial hyperresponsive-
ness and that, in combination with bronchial hyperrespon-
siveness it was very specific for diagnosis of asthma.
Periodically high concentrations of SO2 can have an 
important influence on the maintenance of the same degree 
of bronchial sensitivity despite treatment with anti-inflam-
matory medicines. After administering anti-inflammatory 
medicines, bronchial reactivity in every second asthmatic 
child (59%) is good. A fast change of bronchial reactivity 
in the remaining asthmatic children (41%) is contributed 
by aero-pollution with SO2 and/or possibly insufficient and 
inadequate treatment effect. We conducted our research 
in urban environment, whereas according to the findings 
of Davies and Magnussen [20] the concentrations of SO2 
have been significantly increasing in rural areas during 
the last few decades as a result of boiler rooms, which is 
all reflected by increased morbidity of children suffering 
from respiratory and allergic diseases.
In May and June 2006 and 2008, we expected increased 
concentration of pollens in the air consisting mainly of 
grass pollen and of tree pollen, but we could not predict 
high concentrations of aero-pollutans. The data on 
exceeded allowable concentrations of SO2 of over 150 μg/
m3 per day, soot concentrations of over 50 μg/m3 per day 
and concentrations of total deposited substances of over 
450 μg/m3 per day (minimally permitted concentration – 
MPC) was obtained after the completed research.
A grain of pollen attached to an aero-pollutant (ozone, 
SO2, nitric dioxide – NO2) has a greater influence on the 
increased release of histamine from the basophiles of a 
child with sensitivity to pollen [21]. In June both of 2006 
and 2008, when we conducted the study on bronchial 
hyperresponsiveness in children, SO2 exhibited a harm-
ful effect on airway mucosa during a short period time. 
Neither the quantity of total deposited substances, nor 
the quantity of soot is a predictive factor of bronchial 
hyperresponsiveness. However, after a prolonged effect, 
in conjunction with SO2, it contributes to the change of 
bronchial responsiveness in children. Devalia et al. [22] 
consider that SO2 provokes respiratory symptoms partic-
ularly dyspnoea, airway inflammation, and if combined 
with NO2, it causes a strong bronchoconstriction in asth-
matic children, decreases PD20 for 60.5%, causes dyspnoea 
and aggravates anaphylactic reaction. Bronchial hyperre-
sponsiveness in asthmatic children to inhaled allergens is 
increased and maintained for 24 to 48 hours if the patient 
is exposed to inhalation of SO2 in concentrations of 200 
ppb (400 μg/m3).
A periodically high concentrations of SO2 and a high 
quantity of total deposited substances over longer peri-
ods of time prior to this research, aggravated the antigen 
effect of pollen on airway mucosa. Moreover, they caused 
extensive inflammation, as well as airway reactivity, i.e. 
airway sensitivity mainly in children who had previously 
exhibited the symptoms of wheezing bronchitis, bronchial 
asthma, allergic rhinitis (hay fever) and/or atopic eczema. 
Taking into consideration that the school year ends in May 
and June, children spent more time at home (closed envi-
ronment), so that the cumulative effect of pollen was only 
slightly detectable; contrarily, the onset of the cumulative 
effect of dust mite, house dust mite, house dust and other 
allergens in home environment could be clearly detected.
Bronchial reactivity in asthmatic children is multifacto-
rially controlled. Immune, endocrine and nervous systems 
present a cohesive system of defence, and if the balance 
is disturbed in just one of them, a set of secondary exact 
consequences takes place in the remaining two systems. 
The consequences of the disturbed balance of the system 
in charge are corrected by anti-inflammatory and immu-
nomodulatory therapy taken during the course of a couple 
of months, even years until the high bronchial sensitivity 
and low bronchial reactivity are reached. The bronchial 
responsiveness, mainly symptomatic, is increased both by 
biological risks, as well as by environmental risks, such as 
aero-pollution and pollen season.
Anti-inflammatory therapy by GINA and NAEPP is 
not as efficient as we expect. There is a possibility which 
could be taken into consideration that treatment with 
PRACTALL [23] could yield more desirable therapeutic 
effects.
CONCLUSION
According to our study, the optimal duration of anti-
inflammatory treatment in asthmatic children who show 
moderate bronchial hyperresponsiveness should be longer 
than two years. Currently, we should take into consider-
ation the possibility for a need of different consensus from 
the one we have been using.321
www.srp-arh.rs
Srp Arh Celok Lek. 2011;139(5-6):316-321
REFERENCES
1.  British Thoracic Society. The British Guideline on the Management 
of Asthma. Thorax. 1997; 52(Suppl 1).
2.  Nielsen KG, Bisgaard H. The effect of inhaled budesonide on 
symptoms, lung function, and cold air and methacholine 
responsiveness in 2- to 5-year-old asthmatic children. Am J Respir 
Crit Care Med. 2000; 162(4 Pt 1):1500-6.
3.  Rabinovitch N, Gelfand EW, Leung DYM. The role of immunoglobu-
lin therapy in allergic diseases. Allergy. 1999; 54(7):662-8.
4.  Global Strategy for Asthma Management and Prevention 2006. The 
Global Initiative for Asthma; 2006.
5.  National Asthma Education and Prevention Program. NAEPP expert 
panel report: guidelines for the diagnosis and management of 
asthma – update on selected topics 2002. Bethesda: National 
Institutes for Health; 2006.
6.  Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial 
reactivity to inhaled histamine: a method and clinical survey. J 
Allergy Clin Immunol. 1977; 7:235-43.
7.  Chinn S, Burney P, Jarvis D, Luczynska C. Variation in bronchial 
responsiveness in the European Community Respiratory Health 
Survey (ECRHS). Eur Respir J. 1997; 10:2495-501.
8.  Peat JK, Toelle BG, Salome CM, Woolcock AJ. Predictive nature of 
bronchial responsiveness and respiratory symptoms in a one year 
cohort study of Sydney schoolchildren. Eur Respir J. 1993; 
6(5):662-9.
9.  Ulrik CS. Factors associated with increased bronchial responsive-
ness in adolescents and young adults: the importance of adjust-
ment for prechallenge FEV1. J Allergy Clin Immunol. 1996; 
97(3):761-7.
10.  Siersted HC, Mostgaard G, Hyldebrandt N, Hansen HS, Boldsen J, 
Oxhoj H. Interrelationships between diagnosed asthma, asthma-
like symptoms, and abnormal airway behaviour in adolescence: the 
Odense Schoolchild Study. Thorax. 1996; 51(5):503-9.
11.  Backer V. Bronchial hyperresponsiveness in children and adoles-
cents. Danish Med Bull. 1995; 42(5):397-409.
12.  Hansen KK, Laursen EM, Backer V, Bach-Mortsnsen N, Prahl P, Koch 
C. Bronchial responsiveness in children and adolescents: a 
comparison between previously asthmatic, currently asthmatic, 
and normal subjects. J Asthma. 1994; 31(2):99-107.
13.  Hopp JR, Bewtra KA, Nair MN, Townley GR. Specifity and sensitivity 
of methacholine inhalation challenge in normal and asthmatic 
children. J Allergy Clin Immunol. 1984; 74:154-8.
14.  Popp W, Böck A, Herkner K, Wagner C, Zwick H, Sertl K. Factors 
contributing to the occurrence and predictability of bronchial 
hyperresponsiveness to methacholine in children. J Allergy Clin 
Immunol. 1994; 93(4):735-41.
15.  Devereux G, Hendrick DJ, Stenon SC. Perception of respiratory 
symptoms after methacholine-induced bronchoconstriction in a 
general population. Eur Respir J. 1998; 12:1089-93.
16.  Avital A, Godfrey S, Springer C. Exercise, methacholine, and 
adenosine 5’-monophosphate challenges in children with asthma: 
relation to severity of the disease. Pediatr Pulmonol. 2000; 
30(3):207-14.
17.  Barr J, Rapoport MJ, Tauber T, Hertzianu I, Cafri Y, Bistritzer T. The 
relation between adrenal function and the severity of bronchial 
hyperresponsiveness in children as measured by the methacholine 
provocation test. J Pediatr Endocrinol Metab. 2002; 15(3):307-12.
18.  Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized 
corticosteroid for persistent asthma. J Allergy Clin Immunol. 2002; 
109(4):730-42.
19.  Sunyer J, Antó JM, Castellsaqué J, Soriano JB, Roca J, and the 
Spanish Group of the European Study of Asthma. Total serum IgE is 
associated with asthma independently of specific IgE levels. Eur 
Respir J. 1996; 9:1880-4.
20.  Davies RJ, Magnussen H. Is pollution a cause or a trigger for the 
increase in allergic disease? Allergy. 1997; 52(Suppl 38).
21.  Woodcock A. Asthma and the environment: proceeding of the 
Symposium held on November 7-8, 1996; 1996 Nov 7-8 Wiesbaden 
Eur Respir Rev. 1998; 8(53):131-82.
22.  Devalia JL, Rusznak C, Wang J, Davies RJ. Pollution–allergen 
interactions: challenge studies in man. Eur Respir Rev. 1998; 
8(53):175-8.
23.  Bacharier LB, Boner A, Carlsen KH, Eigemann PA, Frischer T, Götz M, 
et al; European Pediatric Asthma Group. Diagnosis and treatment 
of asthma in childhood: a PRACTALL consensus report. Allergy. 
2008; 63(1):5-34.
КРА ТАК  СА ДР ЖАЈ
Увод П р е  о  се  тљ и  в о с т  б р о н  х и  ј а  ј е  ч и  н и  л а ц  п р е д  в и  ђ а  њ а  б р о н -
хи јал не  аст ме  не за ви сно  од  по ка за те ља  запаљења.
Циљ ра  да Циљ ра  да је био да се од  ре  де уче  ста  лост и зна-
ч а ј  н и   ф а к  т о  р и   п р е д  в и  ђ а  њ а   п р е  о  с е  т љ и  в о  с т и   б р о н  х и  ј а ,   т е  
у с т а  н о  в и   д е ј  с т в о   п р о  ф и  л а к  т и ч  к е   т е  р а  п и  ј е   п р е  п и  с а  н е   п р е -
м а  к о н  с е н  з у  с и  м а  Гл о  б а л  н е  и н  ц и  ј а  т и  в е  з а  а с т  м у  (е н г л .  Glo bal 
Ini ti a ti ve for Asthma – GI NA) и аме рич ког На ци о нал ног про гра-
ма за еду ка ци ју о аст ми и пре вен ци ји (енгл. Na ti o nal Asthma 
Edu ca tion and Pre ven tion Pro gram – NA EPP) на пре о се тљи во ст 
брон хи ја  код  де це  обо ле ле  од  брон хи јал не  аст ме.
М е  т о  д е   р а  д а   П р е  о  с е  т љ и  в о с т   б р о н  х и  ј а   ј е   п р о  ц е  њ и  в а  н а  
б р о н  х о  п р о  в о  к а  ц и ј  с к и м   т е  с т о м   м е  т а  х о  л и  н о м   к о д   10 6   д е  ц е  
са  брон хи јал ном  аст мом.
Ре зул та ти П р е  в а  л е н  ц и  ј а  п р е  о  с е  т љ и  в о  с т и  б р о н  х и  ј а  п р а  ћ е -
не симп то ми ма обо ље ња би ла је 18% са про сеч ном про во-
ци ра ју ћом кон цен тра ци јом PC20 од 4,1±3,03 mg/ml и про во-
ц и  р а  ј у  ћ о м   д о  з о м   PD20 од 3,22±2,59 μmol  м е  т а  х о  л и  н а .   Д е  ц а  
обо ле ла од аст ме по ка зу ју углав ном уме ре ну пре о се тљи вост, 
што се одр жа ва и на кон две го ди не про фи лак тич ке те ра пи-
је. По сле овог пе ри о да ле че ња брон хи јал на ре ак тив ност је 
би ла сла би ја, про ме на FEV1 зна чај но ма ња, бр зи на про ме не 
н а  г и  б а   к р и  в у  љ е   д о  з а   –   о д  г о  в о р   б р  ж а ,   п р о  в о  ц и  р а  ј у  ћ а   к о н -
цен тра ци ја  ко ја  узро ку је  ши шта ње  у  гру ди ма  (ви зинг)  два-
три  пу та  ма ња,  док  је  брон хо ди ла та циј ски  од го вор  био  не-
знат но  бр жи.  Бла ге  кри ву ље  до за  –  од го вор  ука зу ју  на  бла-
жу  брон хо кон стрик ци ју  по сле  две  го ди не  при ме не  про фи-
л а к  т и ч  к е  т е  р а  п и  ј е .  А е р о з а  г а  ђ е  њ е ,  о д  н о  с н о  н е  а  д е  к в а т  н о  л е -
ч е  њ е   б и  л и   с у   р а з  л о г   б р  ж е   п р о  м е  н е   б р о н  х и  ј а л  н е   р е  а к  т и в -
но сти код 41% де це на кон две го ди не. Исто вре ме ни и ду го-
трај ни  ути цај  алер ге на  из  кућ не  сре ди не  и  по вре ме но  ви-
со  к а  к о н  ц е н  т р а  ц и  ј а  з а  г а  ђ е  њ а  в а  з д у  х а  п о  т е н  ц и  р а  л и  с у  а н  т и -
г е н  с к о   д е ј  с т в о   п о  л е  н а   т р а  в а   и   д р  в е  ћ а   н а   с л у  з о  к о  ж у   д и  с а ј -
н и х   п у  т е  в а ,   п о  ј а ч а  в а  л и   о с е  т љ и  в о с т   б р о н  х и  ј а ,   п о  с е б  н о   к о д  
д е  ц е  а т о  п и ј  с к е  к о н  с т и  т у  ц и  ј е ,  и  и н  т е н  з и  в и  р а  л и  и с  п о  љ а  в а  њ е  
симп то мат ске пре о се тљи во сти брон хи ја. По сле две го ди не 
при ме не про фи лак тич ке те ра пи је, пре ма кон сен зу су GI NA и 
NA EPP, де  ца ни  су има  ла симп  то  ме аст  ме или су се код њих 
и с  п о  љ а  в а  л и   б л а  г и   с и м п  т о  м и   о б о  љ е  њ а ,   а л и   ј е   о  с е  т љ и  в о с т  
б р о н  х и  ј а   о с т а  л а   н е  п р о  м е  њ е  н а .
За кљу чак О п  т и  м а л  н а  д у  ж и  н а  а н  т и  и н  ф л а  м а  т о р  н е  т е  р а  п и  ј е  
брон хи јал не  аст ме  код  де це  код  ко је  се  ис по ља ва  уме ре на 
п р е  о  с е  т љ и  в о с т  б р о н  х и  ј а  т р е  б а  д а  б у д е  д у  ж а  о д  д в е  г о  д и  н е .
Кључ не  ре чи:  п р е  о  с е  т љ и  в о с т   б р о н  х и  ј а ;   д е  ц а ;   б р о н  х и  ј а л -
на аст  ма
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